COX–2 Inhibitors act by selectively inhibiting the transformation of arachidonic acid into prostaglandin H2 without affecting the COX–1 enzyme receptors. Due to this selective inhibition ...

In the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), researchers addressed this uncertainty by using lumiracoxib, a highly selective COX-2 inhibitor that has been ...

Non-selective COX-2 inhibitors, such as aspirin and ibuprofen, also reduced the risk of breast cancer. This study highlights the potential of nonsteroidal anti-inflammatory drugs (NSAIDs) for the ...

For example, you shouldn’t take selective COX-2 inhibitors if you have any of the following medical conditions: Selective COX-2 inhibitors are a type of NSAID used for treating pain and ...

Therefore, it may be considered a potential target for preventing and possibly ... anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors as protective agents varies according to the ...

Since the safety of COX-2 inhibitors has not been evaluated in sufficient numbers of patients at high risk of cardiovascular adverse events, it would be wise to consider caution in such groups.

A single-blind, placebo-controlled oral challenge with the highly selective COX-2 inhibitor etoricoxib was carried out in a supervised hospital setting. A nonpruritic exanthem limited to the ...

To examine the effect of nepafenac, a selective cyclooxygenase-2 (COX-2) inhibitor, on the proliferation rate of two human retinoblastoma (Rb)cell lines. Two human Rb cell lines (WERI-RB and Y79 ...

New research on the COX-2 pathway indicates that it might be possible for COX-2 drugs to achieve anti-inflammatory protection, without the cardiovascular risk, by developing drugs that target another ...

Stephen Paget answers the question: 'COX-2 Inhibitors & Rheumatoid Pain ... So new drugs called COX-2 selective non-steroidal inflammatories, because they only inhibit certain enzymes and ...

Regular use of selective COX-2 inhibitors significantly reduces the risk of breast cancer. A case-control study published today in the open access journal BMC Cancer observed that daily use of ...